Abbott Laboratories (ABT)vsBio-Rad Laboratories Inc (BIO)
ABT
Abbott Laboratories
$105.46
-1.61%
HEALTHCARE · Cap: $183.26B
BIO
Bio-Rad Laboratories Inc
$264.49
-0.19%
HEALTHCARE · Cap: $7.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 1616% more annual revenue ($44.33B vs $2.58B). BIO leads profitability with a 29.4% profit margin vs 14.7%. BIO appears more attractively valued with a PEG of 1.19. BIO earns a higher WallStSmart Score of 60/100 (C).
ABT
Buy51
out of 100
Grade: C-
BIO
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-323.7%
Fair Value
$24.89
Current Price
$105.46
$80.57 premium
Margin of Safety
-55.1%
Fair Value
$189.38
Current Price
$264.49
$75.11 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
3.9% revenue growth
Weak financial health signals
Earnings declined 83.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : BIO
The strongest argument for BIO centers on P/E Ratio, Price/Book, Altman Z-Score. Profitability is solid with margins at 29.4% and operating margin at 8.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BIO
The primary concerns for BIO are Revenue Growth, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
BIO carries more volatility with a beta of 1.20 — expect wider price swings.
ABT is growing revenue faster at 4.4% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BIO scores higher overall (60/100 vs 51/100), backed by strong 29.4% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?